GLP-1 receptor agonist and use thereof

Disclosed are novel compounds of Chemical Formula 1, optical isomers of the compounds, and pharmaceutically acceptable salts of the compounds or the optical isomers. The compounds, isomers, and salts exhibit excellent activity as GLP-1 receptor agonists. In particular, they, as GLP-1 receptor agonis...

Full description

Saved in:
Bibliographic Details
Main Authors Heo, Jaeho, Oh, Changmok, Jang, Eun Hye, Kwon, Sung Wook, Lee, Myong Jae, Kim, Gunhee, Kim, Jeong-geun, An, Kyung Mi, Jeon, Woo Jin, Je, In-Gyu, Choi, Ji Hye, Yoo, Yeongran, Hong, Changhee, Jun, Yearin, Shin, Jae Eui, Im, A-rang, Jeong, Jin Ah, Chang, Min Whan, Park, Jung-eun, Sohn, Te-ik, Lee, Jin Hee, Kim, Kyeojin, Yoon, Hong Chul, Hong, Da Hae, Kim, Jung Ho
Format Patent
LanguageEnglish
Published 09.05.2023
Subjects
CHEMISTRY
HETEROCYCLIC COMPOUNDS
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online AccessGet full text

Cover

More Information
Summary:Disclosed are novel compounds of Chemical Formula 1, optical isomers of the compounds, and pharmaceutically acceptable salts of the compounds or the optical isomers. The compounds, isomers, and salts exhibit excellent activity as GLP-1 receptor agonists. In particular, they, as GLP-1 receptor agonists, exhibit excellent glucose tolerance, thus having a great potential to be used as therapeutic agents for metabolic diseases. Moreover, they exhibit excellent pharmacological safety for cardiovascular systems.
Bibliography:Application Number: US202017777193